Vivoryon Therapeutics NV (WBO:VVYN) Ending Cash Position: €5.62 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:VVYN Vivoryon Therapeutics NV WBO:VVYN
16 GF Score
Price €1.13
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV Ending Cash Position?

Vivoryon Therapeutics NV WBO:VVYN 16 Ending Cash Position is €5.62 Mil as of Dec. 2025. GuruFocus rates WBO:VVYN with a GF Score™ of 16/100. The stock has 2 warning signs investors should review.

Vivoryon Therapeutics NV's Ending Cash Position for the quarter that ended in Dec. 2025 was €5.62 Mil.

Vivoryon Therapeutics NV's quarterly Ending Cash Position declined from Dec. 2024 (€9.37 Mil) to Jun. 2025 (€4.84 Mil) but then increased from Jun. 2025 (€4.84 Mil) to Dec. 2025 (€5.62 Mil).

Vivoryon Therapeutics NV's annual Ending Cash Position declined from Dec. 2023 (€18.56 Mil) to Dec. 2024 (€9.37 Mil) and declined from Dec. 2024 (€9.37 Mil) to Dec. 2025 (€5.62 Mil).

Vivoryon Therapeutics NV Ending Cash Position Related Terms

Vivoryon Therapeutics NV Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Vivoryon Therapeutics NV's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV Ending Cash Position Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.66 26.56 18.56 9.37 5.62

Vivoryon Therapeutics NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.56 15.27 9.37 4.84 5.62
WBO:VVYN
16GF Score
Vivoryon Therapeutics NV WBO:VVYN
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Vivoryon Therapeutics NV's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=9.365+-3.746
=5.62

Vivoryon Therapeutics NV's Ending Cash Position for the quarter that ended in Dec. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=4.837+0.782
=5.62

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €5.62 Mil mean?
Vivoryon Therapeutics NV (WBO:VVYN) has a Ending Cash Position of €5.62 Mil as of Dec. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vivoryon Therapeutics NV and its competitors.
Is Vivoryon Therapeutics NV's Ending Cash Position too high?
Vivoryon Therapeutics NV's current Ending Cash Position is €5.62 Mil. Overall, Vivoryon Therapeutics NV has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's Ending Cash Position compare to VRTX and REGN?
Vivoryon Therapeutics NV's Ending Cash Position of €5.62 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current Ending Cash Position is €5.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (WBO:VVYN) has a current Ending Cash Position of €5.62 Mil. The current Ending Cash Position is €5.62 Mil. Vivoryon Therapeutics NV's overall GF Score™ is 16/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Vivoryon Therapeutics NV (WBO:VVYN), the current Ending Cash Position is €5.62 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
16GF Score

Get the complete analysis for WBO:VVYN

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.13
Price